BioAge Labs Reports Positive Interim Phase 1 Data for BGE-102, Demonstrating Strong hsCRP Reduction

summarizeSummary

BioAge Labs announced positive interim Phase 1 data for its novel NLRP3 inhibitor, BGE-102, showing an 86% reduction in hsCRP and a favorable safety profile in patients with elevated cardiovascular risk.

check_boxKey Events

• Positive Interim Phase 1 Data

  BGE-102 achieved an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at Day 14, with 93% of participants reaching normalized levels (<2 mg/L) in obese individuals with elevated cardiovascular risk.

• Best-in-Class Potential Indicated

  The data suggests BGE-102 has the potential for best-in-class hsCRP reduction, along with significant reductions in IL-6 and fibrinogen, key markers of systemic inflammation and cardiovascular risk.

• Favorable Safety Profile

  BGE-102 was well tolerated with a favorable safety profile, showing infrequent, mild to moderate adverse events and no dose-limiting toxicities.

• Advancement to Phase 2a

  The company plans to initiate a Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in 1H 2026, with data readout anticipated in 2H 2026.

auto_awesomeAnalysis

This announcement is highly significant for BioAge Labs as it provides strong clinical validation for BGE-102, a key pipeline asset. The substantial reduction in hsCRP, a critical inflammatory marker for cardiovascular risk, along with reductions in IL-6 and fibrinogen, suggests a potent and potentially best-in-class therapeutic profile. The favorable safety data further de-risks the program. These positive results pave the way for the planned Phase 2a study, which is a crucial next step in demonstrating efficacy in a larger patient population and could significantly impact the company's valuation and future prospects.